Intravenous or enteral loop diuretics for preterm @entity1 with (or developing) XXXX .

@entity1 @entity137 @entity4 @entity26 @entity1483 @entity1030
BACKGROUND: Lung disease in preterm @entity1 is often complicated with @entity4 . OBJECTIVES: The aim of this review was to assess the risks and benefits of administration of a diuretic acting on the loop of Henle (loop diuretic) in preterm @entity1 with or developing @entity1030 ( @entity1030 ). Primary objectives were to assess changes in need for @entity26 or ventilatory support and effects on long-term outcome, and secondary objectives were to assess changes in pulmonary mechanics and potential complications of therapy. SEARCH STRATEGY: We used the standard search method of the Cochrane Neonatal Review Group. We searched MEDLINE (1966-October 2001), EMBASE (1974-November 2001) and the Cochrane Controlled Trials Register (CCTR) (Cochrane Library, Issue 4, 2001). In addition, we hand searched several abstract books of national and international American and European Societies. SELECTION CRITERIA: We included in this analysis trials in which preterm @entity1 with or developing @entity1030 and at least 5 days of age were all randomly allocated to receive a loop diuretic either enterally or intravenously. Eligible studies needed to assess at least one of the outcome variables defined a priori for this systematic review. Primary outcome variables included important clinical outcomes, and secondary outcome variables included @entity137 and pulmonary mechanics (e.g., lung compliance and airway resistance). DATA COLLECTION AND ANALYSIS: We used the standard method for the Cochrane Collaboration which is described in the Cochrane Collaboration Handbook. Two investigators extracted, assessed and coded separately all data for each study, using a form that was designed specifically for this review. Any disagreement was resolved by discussion. We combined parallel and cross-over trials and, whenever possible, transformed baseline and final outcome data measured on a continuous scale into change scores using Follmann's formula. MAIN RESULTS: The only loop diuretic used in the studies which met the selection criteria was @entity1483 . Most studies focused on pathophysiological parameters and did not assess effects on important clinical outcomes defined in this review, or the potential complications of diuretic therapy. In preterm @entity1 < 3 weeks of age developing @entity1030 , @entity1483 administration has either inconsistent effects or no detectable effect. In @entity1 > 3 weeks of age with @entity1030 , a single intravenous dose of 1 mg/kg of @entity1483 improves lung compliance and airway resistance for 1 hour. Chronic administration of @entity1483 improves both oxygenation and lung compliance. REVIEWER'S CONCLUSIONS: In preterm @entity1 > 3 weeks of age with @entity1030 , acute and chronic administration of @entity1483 improve lung compliance. Chronic administration of intravenous or enteral @entity1483 improves oxygenation. In view of the lack of data from randomized trials concerning effects on important clinical outcomes, routine or sustained use of systemic loop diuretics in @entity1 with (or developing) @entity1030 cannot be recommended based on current evidence. Randomized trials are needed to assess the effects of @entity1483 administration on survival, duration of ventilatory support and @entity26 administration, length of hospital stay, potential complications and long-term outcome.
